Replies to post #247633 on Biotech Values

[DewDiligence]

Re: RVNC opportunity in cervical-dystonia and related disorders

What is estimated size of market?

Please see slide #29 in RVNC’s corporate slide set (https://investors.revance.com/static-files/3d765f7c-1d06-49ae-bac4-0fa4cf46a092 ), which shows 2022 market sizes for cervical dystonia ($470M worldwide, $325M US) and for spasticity ($822M worldwide, $654M US). These numbers can be expected to increase in 2023 and future years due to general market growth as well as the specific boost from the availability of a longer-acting toxin that doesn’t wear off between treatments (#msg-155833598).

Will RVNC charge premium price for [cervical dystonia and spasticity] patients?

For therapeutic indications, Daxxify will cost injectors roughly the amount per procedure as Botox. The reason there won’t be a material price premium for Daxxify in therapeutic indications (even though Daxxify carries a 10-40% price premium compared to Botox in aesthetic indications) is explained in #msg-172115594.